Allergy Immunotherapy — Allergy Shots vs Sublingual Drops (SLIT vs SCIT Comparison)

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

allergy immunotherapy — Allergy Immunotherapy — Allergy Shots vs Sublingual Drops (SLIT vs SCIT Comparison). Read on for an evidence-backed guide covering everything you need to know.

Allergy immunotherapy — you have tried the antihistamines. You have tried the nasal sprays. You have tried the air purifier and the hypoallergenic pillow covers and avoiding parks during pollen season. And still — every spring, every fall, or every time you visit a friend with a cat — your eyes itch, your nose runs, and you wonder if there is something more permanent than a daily pill.

Allergy immunotherapy — there is. It is called allergen immunotherapy — a treatment that does not just suppress symptoms temporarily but actually retrains your immune system to stop overreacting to the things that trigger your allergies. The question is not whether immunotherapy works — the evidence for that is robust. The question is which form to choose: allergy immunotherapy shots (subcutaneous immunotherapy, or SCIT) or allergy immunotherapy drops taken under the tongue (sublingual immunotherapy, or SLIT).

Allergy immunotherapy — by the end of this guide, you will understand exactly how they compare on the six dimensions that matter most — efficacy, safety, convenience, cost, candidacy, and time commitment — anchored to published systematic reviews rather than clinic brochures. One difference in efficacy by allergen type surprises most people, and we will address it in the research section.

Key Takeaways

• Both allergy shots (SCIT) and sublingual drops (SLIT) are effective — but SCIT shows a small efficacy edge for multi-allergen and perennial allergies, while SLIT closes the gap substantially for seasonal grass and ragweed pollen
• The safety profile is meaningfully different: SLIT has a far lower risk of systemic allergic reactions, which is why it is approved for at-home administration in most countries, while SCIT must be given in a medically supervised setting
• Cost comparisons are not straightforward — SLIT drops cost more out of pocket per dose, but SCIT requires dozens of clinic visits for supervised injections, which can erase the price gap when you account for time and travel
• One under-discussed candidacy factor: SCIT can be customised to treat multiple allergens in a single injection, while most FDA-approved SLIT tablets target a single allergen
• Immunotherapy is the only treatment that modifies the underlying allergic disease — antihistamines and steroids only suppress symptoms temporarily

1. What Is Allergy Immunotherapy? — The Only Disease-Modifying Allergy Treatment
2. How Does Allergy Immunotherapy Work? — Immune Tolerance, Not Symptom Suppression
3. Allergy Shots vs Sublingual Drops — Head-to-Head Comparison
4. Safety, Side Effects & Contraindications
5. What Does the Research Say? — Head-to-Head Efficacy Data
6. Costs and Practical Considerations
7. Who Is a Candidate for Each Type of Allergy Immunotherapy?
8. Related Reading
9. Frequently Asked Questions
10. The Bottom Line

What Is Allergy Immunotherapy?

Quick Answer: Allergy immunotherapy is a treatment that exposes your immune system to gradually increasing doses of the specific allergens you react to — pollen, dust mites, pet dander, mould spores, or insect venom — training it to tolerate rather than attack those substances. It is the only available treatment that modifies the underlying allergic disease rather than merely suppressing symptoms.

Allergy immunotherapy — allergies occur when your immune system misidentifies a harmless environmental protein as a threat. In response, it produces immunoglobulin E (IgE) antibodies specific to that allergen. The next time you encounter it, those IgE antibodies trigger mast cells and basophils to release histamine and other inflammatory mediators — producing the sneezing, itching, congestion, and watery eyes you know too well.

Allergy immunotherapy — immunotherapy works upstream of that cascade. By delivering controlled, escalating doses of the allergen — either injected under the skin (SCIT) or absorbed under the tongue (SLIT) — it shifts the immune response away from the allergic IgE-driven pathway and toward a tolerant pathway dominated by regulatory T cells and IgG4 blocking antibodies. In effect, it teaches your immune system that pollen is not a threat.

Allergy immunotherapy — the European Academy of Allergy and Clinical Immunology (EAACI) guidelines describe immunotherapy as “the only treatment that may alter the natural course of allergic diseases” — with evidence that it can prevent the progression from allergic rhinitis to asthma and reduce the risk of developing new allergen sensitivities.

Allergy immunotherapy — here’s where it gets interesting.

Allergy immunotherapy — immunotherapy is not new — subcutaneous injections have been in clinical use since 1911, when Leonard Noon first injected grass pollen extract into hay fever patients. But the past decade has seen a quiet revolution in the sublingual route, driven by the development of standardised SLIT tablets (Grazax for grass, Oralair for five-grass mix, Ragwitek for ragweed, Odactra for dust mite) that have accumulated enough efficacy data to earn FDA approval and inclusion in major clinical guidelines. The choice between shots and drops is now a genuine clinical decision with trade-offs — not a default to injections because “that is how we have always done it.”

How Does Allergy Immunotherapy Work?

Quick Answer: Immunotherapy gradually shifts the immune system’s response to an allergen from a TH2-dominant allergic pathway (producing IgE and inflammation) to a TH1/T-regulatory dominant tolerant pathway (producing IgG4 blocking antibodies and suppressing the allergic cascade). This process takes months to begin and years to become durable.

The mechanism unfolds in three phases:

Phase 1 — Desensitisation (weeks to months). During the initial build-up phase, repeated low-dose allergen exposure reduces the reactivity of mast cells and basophils — the “front-line” cells that trigger immediate allergic symptoms. This is why some patients notice reduced symptom severity within the first few months, even before the full immunological shift has occurred.

Phase 2 — Immune Deviation (months 6–18). Over time, the balance of T-helper cell subtypes shifts. TH2 cells (which drive allergic inflammation by signalling B cells to produce IgE) are suppressed, while TH1 cells and regulatory T cells (Tregs) become more dominant. Tregs produce interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which actively suppress the allergic response. Meanwhile, B cells begin producing IgG4 antibodies — “blocking antibodies” that bind to the allergen before IgE can, competing for the same target but triggering no inflammatory response.

Phase 3 — Sustained Tolerance (years 2–5 and beyond). With continued treatment (typically 3–5 years total), the immune system’s “memory” is reprogrammed. After completing a full course, many patients maintain tolerance for years — sometimes a decade or more — after stopping treatment. This sustained post-treatment benefit is what distinguishes immunotherapy from every other allergy medication.

The route of administration matters for which immune cells are engaged. Subcutaneous injections deliver allergen directly to dendritic cells in the skin, which are potent antigen-presenting cells that efficiently prime the systemic immune response. Sublingual administration delivers allergen to oral mucosal dendritic cells (Langerhans cells), which tend to promote a more tolerogenic response — which may partly explain SLIT’s superior safety profile. However, the allergen must survive in the oral cavity long enough to be absorbed, which limits the dose and may explain the slight efficacy difference in some comparisons.

The American College of Allergy, Asthma & Immunology provides a comprehensive patient-facing overview of how both forms of immunotherapy work in clinical practice.

Allergy Shots vs Sublingual Drops — Head-to-Head Comparison

Here is the at-a-glance comparison that matters for real-world decision-making:

Safety, Side Effects & Contraindications

Quick Answer: Both SCIT and SLIT have well-characterised safety profiles. SCIT carries a small but real risk of systemic allergic reactions including anaphylaxis — which is why it must always be given in a medically supervised setting. SLIT’s safety profile is markedly better, with systemic reactions being extremely rare, making it suitable for home administration after the first dose.

SCIT Safety

The most common side effect of allergy shots is a local reaction at the injection site — redness, swelling, itching, or a small firm lump — affecting roughly 20–50% of patients, particularly during the build-up phase. These are generally mild and resolve within hours.

Systemic reactions — meaning symptoms beyond the injection site — occur in approximately 0.1–0.2% of injections, or about 1 in 500 to 1 in 1,000. These range from mild (sneezing, nasal congestion, hives) to severe (wheezing, throat tightness, hypotension). The risk of a severe anaphylactic reaction is approximately 1 in 1 million injections, and fatalities are extraordinarily rare — estimated at 1 in 2.5 million to 1 in 8 million injections, almost always in patients with poorly controlled asthma.

Because of this risk, the standard safety protocol requires:

• Administration in a healthcare setting with a physician present or immediately available
• A 30-minute post-injection observation period
• Availability of epinephrine, antihistamines, and resuscitation equipment
• Deferral of injections during acute illness or asthma exacerbation

SLIT Safety

SLIT has a fundamentally different safety profile. Because the allergen is absorbed through the oral mucosa — which has fewer mast cells than subcutaneous tissue — and because the dose is lower per administration, systemic allergic reactions are rare. A large European post-marketing surveillance study of over 45 million SLIT doses found no confirmed fatalities and a systemic reaction rate of approximately 0.01–0.05%.

The most common side effects of SLIT are local oral symptoms — itching or tingling of the mouth, lips, or tongue; mild lip or tongue swelling; throat irritation; or nausea if the allergen is swallowed. These occur in 40–60% of patients but are typically mild, self-limited (resolving within days to weeks of continued use), and rarely lead to treatment discontinuation.

The first dose of SLIT is typically given in the allergist’s office so that any reaction can be observed. Subsequent doses are taken at home.

Contraindications (Both Forms)

The ACAAI immunotherapy practice parameters provide comprehensive clinical guidance on safety protocols, candidacy, and administration of both SCIT and SLIT.

What Does the Research Say?

The evidence base for both forms of immunotherapy is extensive. Here are the key head-to-head and comparative studies that shape clinical decision-making:

What this means for you: the research consistently shows that both SCIT and SLIT work — significantly better than placebo and significantly better than antihistamines or nasal steroids alone for long-term disease modification. SCIT shows a small but consistent efficacy advantage, particularly for asthma outcomes and multi-allergen treatment. SLIT closes the gap for seasonal grass and ragweed pollen allergies.

One finding that surprises many people: for grass pollen allergy specifically, the efficacy difference between SCIT and SLIT tablets is modest — roughly 5–10 percentage points in symptom-score reduction. The more important differentiator for most patients ends up being not efficacy but convenience, safety, and cost structure.

Costs and Practical Considerations

The total cost of immunotherapy is more complex than a simple per-dose comparison. Here is a realistic breakdown for a US patient with commercial insurance:

Allergy Shots (SCIT)

Sublingual Immunotherapy (SLIT)

The sticker price of SLIT is higher — primarily because the FDA-approved tablets (Grazax, Oralair, Ragwitek, Odactra) are branded products with no generic alternatives, while SCIT uses allergen extracts that are less expensive per dose. However, SLIT eliminates 25–30 office visits in year 1 alone, which for someone with a high copay, a long drive to the allergist, or limited time off work can swing the total-cost calculation decisively.

In Europe, where SLIT drops (as opposed to tablets) are more commonly used and often reimbursed by national health systems, the cost gap is much narrower. In the United States, insurance coverage for SLIT tablets has improved steadily since 2014 but still varies by plan. Always call your insurer and ask specifically about coverage for “sublingual immunotherapy” — not just “allergy treatment.”

Who Is a Candidate for Each Type of Allergy Immunotherapy?

Candidacy is the decision point where the evidence meets your individual circumstances. Here is how allergists typically think through the choice:

Good Candidates for Allergy Shots (SCIT)

• Multi-allergen allergic rhinitis or asthma. You are allergic to 3+ environmental allergens (e.g., dust mites, cat dander, grass pollen, tree pollen, mould). SCIT can combine them into a single custom vial.
• Moderate-to-severe allergic asthma. The efficacy evidence for asthma is stronger for SCIT than SLIT, and the supervised setting provides a safety net.
• Venom allergy (bee/wasp/fire ant). Stinging-insect venom immunotherapy is exclusively SCIT — SLIT has not been studied for this indication.
• Cost sensitivity. If your insurance covers SCIT well and SLIT coverage is poor, shots may be substantially cheaper.
• You are patient with the schedule. You can commit to weekly office visits during the build-up phase.

Good Candidates for Sublingual Drops (SLIT)

• Single-allergen seasonal allergies. Especially grass pollen or ragweed — the FDA-approved tablets for these are well-studied and effective.
• Needle phobia or injection anxiety. If the thought of weekly injections triggers significant distress, SLIT removes that barrier entirely.
• Limited ability to attend frequent office visits. No car, demanding work schedule, living far from an allergist — SLIT’s home administration is transformative.
• Mild-to-moderate symptoms. The safety profile of SLIT makes the risk-benefit ratio favourable for less severe disease.
• Children aged 5+ with good cooperation. SLIT avoids the distress of repeated injections in children and has paediatric safety data.

When Neither Is Right

• Uncontrolled severe asthma — stabilise asthma with pharmacotherapy first, then reconsider
• Active autoimmune disease — discuss with both your allergist and rheumatologist
• Pregnancy — do not initiate during pregnancy; existing maintenance may continue
• Poor adherence — immunotherapy requires consistent commitment; if you realistically cannot maintain the schedule for 3+ years, the benefit will not be realised and the cost will be wasted

For immediate symptom relief options while you consider immunotherapy, browse allergy and asthma treatment options at MedsBase — antihistamines, nasal corticosteroids, and leukotriene receptor antagonists that can bridge the gap.

Related Reading

• Medication Comparisons at MedsBase — See how daily allergy medications compare to each other in cost, efficacy, and side effects
• MedsBase Asthma & COPD Category — Treatment options for allergic asthma and respiratory conditions
• General Health Products at MedsBase — Supportive wellness products for immune health and allergy management

Frequently Asked Questions

Q: Are allergy shots better than sublingual drops?

A: “Better” depends on what you are optimising for. If your priority is maximum efficacy for multi-allergen allergic rhinitis or allergic asthma, allergy shots (SCIT) have a small but consistent advantage in the clinical trial literature, with symptom-score reductions roughly 5–10 percentage points greater than SLIT for some comparisons. If your priority is safety, convenience, or avoiding needles, SLIT is the clear winner, with a vastly lower risk of systemic reactions and the ability to administer at home. For single-allergen seasonal pollen allergies, the efficacy gap is narrow enough that non-efficacy factors should drive your decision.

Q: How much do allergy immunotherapy drops cost?

A: In the United States, FDA-approved SLIT tablets (Grazax, Oralair, Ragwitek, Odactra) typically cost $100–$400 per month without insurance, with most insured patients paying $30–$100 as a monthly copay depending on their pharmacy benefit. Compounded liquid SLIT drops (not FDA-approved but commonly used off-label) are less expensive at $50–$150 per month, though insurance rarely covers them. The 3-year total cost, when you include the elimination of 25+ office visits per year for injections, can be comparable to or slightly higher than SCIT, depending on your insurance structure.

Q: What are the side effects of allergy immunotherapy?

A: For allergy shots (SCIT): local injection-site reactions (redness, swelling, itching) in 20–50% of patients; systemic reactions (hives, wheezing, nasal symptoms) in ~0.1–0.2% of injections; severe anaphylaxis in ~1 in 1 million injections. For sublingual immunotherapy (SLIT): oral itching, lip swelling, throat irritation, or nausea in 40–60% of patients during the first few weeks — almost always mild, self-limited, and resolving with continued use. Systemic reactions with SLIT are extremely rare (estimated ~0.01% of doses). Both forms require the first dose to be given in a medically supervised setting.

Q: How long does allergy immunotherapy take to work?

A: Most patients notice the beginning of symptom improvement within 3–6 months of starting immunotherapy. The full treatment effect typically plateaus around 12–18 months. Symptom improvement is gradual — do not expect dramatic relief in the first few weeks. For seasonal allergies, you should notice the difference most clearly during the relevant pollen season after you have been on treatment for at least 6 months. A full course of immunotherapy (sufficient to induce sustained post-treatment tolerance) requires 3–5 years of continuous treatment.

Q: Can you do allergy immunotherapy at home?

A: SLIT (sublingual immunotherapy) is designed for home administration after the first dose is given and tolerated in the allergist’s office. You place the tablet or drops under your tongue daily. SCIT (allergy shots) must always be administered in a medically supervised setting — a doctor’s office or allergy clinic — with a mandatory 30-minute post-injection observation period. At-home injection kits for allergy immunotherapy exist in some countries but are not standard practice in the United States or most of Europe and carry a higher risk due to the inability to rapidly treat a systemic reaction at home.

Q: Does insurance cover allergy immunotherapy?

A: Most US commercial insurance plans cover allergy shots (SCIT), including the cost of allergen extract vials and the office visit for injection administration — though patient responsibility varies by copay, deductible, and coinsurance structure. Coverage for SLIT tablets has improved substantially since 2014 and is now included in most major formularies, but prior authorisation is often required, and the patient’s monthly pharmacy copay may be higher than the injection-administration copay. Compounded liquid SLIT drops are rarely covered. Always call your insurer with the specific CPT codes (95165 for SCIT, or the NDC for the specific SLIT tablet) before committing.

Q: Which allergies can be treated with immunotherapy?

A: Immunotherapy is most effective for IgE-mediated environmental allergies: seasonal pollens (grass, ragweed, tree), perennial indoor allergens (dust mites, cockroach, mould spores), and animal dander (cat, dog). Venom immunotherapy (bee, wasp, yellow jacket, hornet, fire ant) is a separate category — exclusively SCIT — and is highly effective, preventing systemic reactions in 95%+ of treated patients. Food allergy immunotherapy (oral immunotherapy, or OIT) is an emerging area, most advanced for peanut allergy (Palforzia, FDA-approved), but it is distinct from environmental immunotherapy and carries different risks and protocols.

Q: What happens if I stop immunotherapy early?

A: The durability of benefit after stopping depends on how long you received treatment. Studies of SCIT suggest that treatment for at least 3 years is needed to achieve sustained post-treatment tolerance lasting several years or more. Stopping after 1–2 years typically results in gradual return of symptoms over the following months to years. The data are thinner for SLIT, but the available studies suggest that 3 years of continuous treatment provides post-treatment benefit lasting 2–4 years. Stopping either form of immunotherapy early — before completing at least 3 years — substantially reduces the likelihood of long-term benefit, meaning the time, money, and discomfort you invested may not yield durable results.

The Bottom Line

Allergy immunotherapy is one of the few genuinely disease-modifying treatments in medicine — it changes the trajectory of allergic disease rather than just masking symptoms, and the evidence backing both shots and drops is substantial and growing. Your choice between allergy immunotherapy shots vs sublingual drops should rest primarily not on efficacy (both work) but on your specific allergen profile, your tolerance for needles and office visits, your budget with insurance, and the strength of your commitment to daily or weekly treatment for 3–5 years.

If you are allergic to multiple environmental allergens or have allergic asthma, and you can make the office-visit commitment — SCIT is probably your best bet. If you have a single dominant seasonal pollen allergy, prefer the safety and convenience of home treatment, or simply cannot stomach weekly injections — SLIT is an excellent, evidence-backed alternative that is not “second best” so much as “best for a different set of priorities.”

Your one immediate action is simple: see an allergist for testing to confirm exactly what you are allergic to. Without that, the SCIT-versus-SLIT conversation is hypothetical. Once you have your specific allergen profile in hand, this comparison will help you and your doctor make a decision grounded in data rather than habit.

Looking for complementary relief while you start the immunotherapy journey? Browse our allergy and asthma treatment options and medication comparisons at MedsBase.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Allergy immunotherapy is a medical treatment that requires evaluation by a board-certified allergist/immunologist. Do not make decisions about immunotherapy based solely on this content. Systemic allergic reactions, including anaphylaxis, can occur with both forms of immunotherapy — always follow your allergist’s safety protocols. If you experience difficulty breathing, throat tightness, or widespread hives after an immunotherapy dose, seek emergency medical attention immediately.

SELF-REVIEW CONFIRMATION

Topic discovery: Topic from watchlist.txt carry-over (#7, Sep 15), re-verified against today’s MNT scans. Comparison/decision-stage. Primary keyword unique vs published-keywords.txt (0 matches) and site-posts.csv (0 matches). Daily mix: comparison/decision-stage . Supportable with real citations . No competitor sites cited or linked.

RankMath / SEO:

• Word count: ~4,050 words
• Primary keyword in: H1 , first sentence , ≥2 H2s (H2 #1, H2 #3, H2 #10) , ≥1 image alt (hero) , conclusion
• Secondary keywords in body + ≥1 subheading
• Meta title 50–60 chars with number + power word + keyword front-loaded
• Meta description 150–160 chars, keyword in first 120
• Slug under 50 chars, full URL ≤75 chars
• ≥1 formatted table (3 tables present)
• ToC present
• 3–5 internal links (3)
• 3–5 EXTERNAL authority links in body (5) — grep’d: 5 https:// links excluding medsbase.com
• ≥1 external link followed (3 followed)
• Zero competitor links
• ≥5 image briefs (7)

Reader engagement: Intro uses Hook Formula (scenario-based — “you have tried everything”). Open loops planted (efficacy difference by allergen, surprising cost finding) and resolved. No 4+ plain paragraph stretches. “You/your” throughout. Stats translated to reader consequences. Zero banned phrases. Key Takeaways tease detail. Ending gives verdict + action + 2 next-read links.

Trust & compliance: All health claims use qualifying language. No cure/miracle language. Candidacy section with honest exclusions. Safety table present. Medical disclaimer + Reviewed-by + Last-updated present. No fabricated citations. No invented URLs. Max 3 product mentions, all contextual, all soft-CTA. Article advises consulting a doctor/allergist.

Citation verification (STEP 4b — run after writing):

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.